Inactive Instrument

All News Amicus Therapeutics Nasdaq

Equities

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

Amicus Therapeutics to Announce First Quarter 2024 Financial Results on May 9, 2024	07:01am	AQ
Amicus Therapeutics : ESG Report	Mar. 20	PU
Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report	Mar. 20	AQ
JPMorgan Adjusts Price Target on Amicus Therapeutics to $19 From $21, Maintains Overweight Rating	Mar. 18	MT
Amicus Therapeutics Insider Sold Shares Worth $389,543, According to a Recent SEC Filing	Mar. 05	MT
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2024	Mar. 04	AQ
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2024	Mar. 01	AQ
Transcript : Amicus Therapeutics, Inc., Q4 2023 Earnings Call, Feb 28, 2024	Feb. 28
Amicus Therapeutics Swings to Q4 Earnings, Revenue Rises	Feb. 28	MT
Earnings Flash (FOLD) AMICUS THERAPEUTICS Posts Q4 EPS $0.01, vs. Street Est of $-0.04	Feb. 28	MT
Amicus Therapeutics, Inc. Provides Earnings Guidance for the Year 2024	Feb. 28	CI
Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates	Feb. 28	AQ
Amicus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Amicus Therapeutics : Fourth Quarter and Full Year 2023 Results Conference Call and Webcast	Feb. 27	PU
Amicus Therapeutics to Announce Full Year 2023 Financial Results on February 28, 2024	Feb. 15	AQ
Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti + Opfolda at the 20th Annual WORLDSymposium	Feb. 09	AQ
Amicus Therapeutics Insider Sold Shares Worth $390,018, According to a Recent SEC Filing	Feb. 08	MT
Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) at the 20th Annual WORLDSymposium™	Feb. 08	AQ
Amicus Therapeutics Announces Presentations and Posters at the 20th Annual WORLDSymposium™ 2024	Feb. 01	AQ
Amicus Therapeutics Insider Sold Shares Worth $683,958, According to a Recent SEC Filing	Jan. 24	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Amicus Therapeutics Nasdaq

Equities

All News

Filters